<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/1561-6274-2004-8-3-62-66</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-862</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>СУТОЧНЫЕ РИТМЫ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ У БОЛЬНЫХ ХРОНИЧЕСКИМ ГЛОМЕРУЛОНЕФРИТОМ И ДИАБЕТИЧЕСКОЙ НЕФРОПАТИЕЙ В СТАДИИ ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ</article-title><trans-title-group xml:lang="en"><trans-title>CIRCADIAN RHYTHMS OF ARTERIAL PRESSURE IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS AND DIABETIC NEPHROPATHY IN THE STAGE OF CHRONIC RENAL FAILURE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мосина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mosina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра пропедевтики внутренних болезней, курс клинической нефрологии и диализа, факультет последипломного обучения</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Есаян</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Essaian</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра пропедевтики внутренних болезней, курс клинической нефрологии и диализа, факультет последипломного обучения</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>А. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantsev</surname><given-names>A. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра пропедевтики внутренних болезней, курс клинической нефрологии и диализа, факультет последипломного обучения</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>10</day><month>03</month><year>2004</year></pub-date><volume>8</volume><issue>3</issue><fpage>62</fpage><lpage>66</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мосина Н.В., Есаян А.М., Румянцев А.Ш., 2004</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="ru">Мосина Н.В., Есаян А.М., Румянцев А.Ш.</copyright-holder><copyright-holder xml:lang="en">Mosina N.V., Essaian A.M., Rumyantsev A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/862">https://journal.nephrolog.ru/jour/article/view/862</self-uri><abstract><p>ЦЕЛЬ ИССЛЕДОВАНИЯ. Оценить роль нарушений суточных ритмов артериального давления (АД) в прогрессировании почечной недостаточности у пациентов с хроническим гломерулонефритом (ХГН) и диабетической нефропатией (ДН), их взаимосвязь с активностью ренинангиотензинальдостероновой системы (РААС). ПАЦИЕНТЫ И МЕТОДЫ. Обследовано 63 пациента с различной степенью почечной недостаточности, из них женщин 34, мужчин 29. Пациентов с ХГН было 33 (52%), ДН – 30 (48%). Все пациенты получали антигипертензивную терапию с целью снижения среднего АД (АДср) до уровня 92 мм рт. ст. (125/ 75 мм рт. ст.). Пациентам выполнялось суточное мониторирование артериального давления (СМАД). В день проведения СМАД определялась активность ренина плазмы (АРП). Скорость прогрессирования хронической почечной недостаточности (ХПН) оценивали по времени удвоения уровня креатинина крови. РЕЗУЛЬТАТЫ. Пациенты с ДН и ХГН не отличались по основным лабораторным параметрам, за исключением более выраженной протеинурии у диабетиков. У диперов с ДН скорость прогрес сирования ХПН составила 27,8±3,7 мес., при нарушенном суточном ритме АД – 21,2±4,4 мес. В группе больных ХГН скорость прогрессирования ХПН была существенно ниже у диперов, чем у больных с нарушенным суточным профилем АД (44,0±5,5 и 24,3±7,6 мес., соответственно). Больные ХГН и ДН с нарушенным суточным ритмом АД имели примерно одинаковую скорость прогрессирования ХПН (24,3±7,6 и 21,2±4,4 мес., соответственно; Mann–Whitney U test; Z = – 1,0; p = 0,9). Скорость прогрессирования ХПН у диперов с ДН составила 27,8±3,7 месяца, при ХГН – 44,0±5,5 месяца (Mann–Whitney U test; Z = 2,0; p = 0,04). Такая же закономерность наблюдалась и в случае достигнутого и недостигнутого целевого уровня АД (25,4±6,4 и 20,4±3,5 мес., соответственно; Mann–Whitney U test; Z = 0,34; p = 0,74). ЗАКЛЮЧЕНИЕ. Скорость прогрессирования ХПН у больных с ДН выше, чем при ХГН при нормальном суточном ритме или достигнутом целевом уровне АД. Больные ХГН и ДН с нарушенным суточным ритмом или недостигнутым целевым уровнем АД имели примерно одинаковую скорость прогрессирования ХПН.</p></abstract><trans-abstract xml:lang="en"><p>THE AIM of the investigation was to assess the role of impairments of circadian rhythms of arterial pressure (AP) in progression of renal failure in patients with chronic glomerulonephritis (CGN) and diabetic nephropathy (DN), their interrelation with activity of reninangiotensin aldosteron system. PATIENTS AND METHODS. Examination of 63 patients with different degrees of renal failure included 34 women and 29 men. There were 33 patients (52%) with CGN and 30 (48%) with DN. All the patients received antihypertensive therapy in order to reduce average AP .to the level of 92 mm Hg (125/75 mm Hg). Circadian monitoring of AD (CMAD) was performed in all the patients. On the day of CMAD plasma renin activity was specified. The rate of progressing chronic renal failure (CRF) was specified by the time of doubling the blood creatinin level. RESULTS. Patients with DN and CRF did not differ by the main laboratory parameters with the exception of more pronounced proteinuria in diabetics. In dipers with DN the rate of progression of CRF was 27.8+3.7 months, with the impaired circadian rhythm of AP 21.2+4.4 months. In the group of patients with CGN the rate of progression of CRF was substantially slower in dipers than in patients with impaired circadian profile of AP (44.0±5.5 and 24.3±7.6 months respectively). Patients with CGN and DN with the impaired circadian rhythm had approximately similar rate of progression of CRF (24.3±7.6 and 21.2±4.4 months respectively; MannWhitney U test; Z = 1.0; p= 0.9). The rate of progression of CRF in dipers with DN was 27.8±3.7 months, with CGN 44.0±5.5 months (MannWhitney U test; Z = 2.0; p=0.04). The same regularity was also observed in cases of the achieved and not achieved required level of AP (25.4±6.4 and 20.4±3.5 months respectively; MannWhitney U test; Z = 0.34; p=0.74). CONCLUSION. The rate of progression of CRF in patients with DN was higher than with CGN with the normal circadian rhythm or the achieved required level of AP. Patients with CGN and DN with the impaired circadian rhythm or not achieved required level of AP had approximately similar rate of progression of CRF.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хроническая почечная недостаточность</kwd><kwd>артериальное давление</kwd><kwd>суточные ритмы</kwd><kwd>ренин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic renal failure</kwd><kwd>arterial pressure</kwd><kwd>circadian rhythms</kwd><kwd>renin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease J Am Soc Nephrol 1998; 9 (12): 3142</mixed-citation><mixed-citation xml:lang="en">Meyer KB, Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: report from the National Kidney Foundation Task Force on cardiovascular disease J Am Soc Nephrol 1998; 9 (12): 3142</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Peterson J, Adler S, Burkart J, et al. Blood pressure control, proteinuria and the progression of renal disease Ann Intern Med 1995; 123: 754762</mixed-citation><mixed-citation xml:lang="en">Peterson J, Adler S, Burkart J, et al. Blood pressure control, proteinuria and the progression of renal disease Ann Intern Med 1995; 123: 754762</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36: 894</mixed-citation><mixed-citation xml:lang="en">Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000; 36: 894</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Redon J, Liao Y, Lozano JV et al. Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. J Hypertens 1994; 12 (8): 947953</mixed-citation><mixed-citation xml:lang="en">Redon J, Liao Y, Lozano JV et al. Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. J Hypertens 1994; 12 (8): 947953</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Douglas J, on behalf of the AfricanAmerican Study of Kidney Disease trial investigators. AfricanAmerican Study of Kidney Disease (AASK) trial. African American Study of Kidney Disease and Hypertension. JAMA 2001; 285: 27192728</mixed-citation><mixed-citation xml:lang="en">Douglas J, on behalf of the AfricanAmerican Study of Kidney Disease trial investigators. AfricanAmerican Study of Kidney Disease (AASK) trial. African American Study of Kidney Disease and Hypertension. JAMA 2001; 285: 27192728</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Klag MJ, Whelton PW, Bryan L et al. Blood pressure and endstage renal disease in men. N Engl J Med 1996; 334 (1): 1318</mixed-citation><mixed-citation xml:lang="en">Klag MJ, Whelton PW, Bryan L et al. Blood pressure and endstage renal disease in men. N Engl J Med 1996; 334 (1): 1318</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285 (21): 27192728</mixed-citation><mixed-citation xml:lang="en">Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285 (21): 27192728</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodelling of left ventricle in hypertensive patients with normal ventricular mass. Am J Coll Cardiol 1995; 25: 871878</mixed-citation><mixed-citation xml:lang="en">Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodelling of left ventricle in hypertensive patients with normal ventricular mass. Am J Coll Cardiol 1995; 25: 871878</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on sodium and blood pressure: a critical review of current scientific evidence. Hypertension 2000; 35: 858863</mixed-citation><mixed-citation xml:lang="en">Chobanian AV, Hill M. National Heart, Lung, and Blood Institute Workshop on sodium and blood pressure: a critical review of current scientific evidence. Hypertension 2000; 35: 858863</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341 (15): 11271133</mixed-citation><mixed-citation xml:lang="en">Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341 (15): 11271133</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837848</mixed-citation><mixed-citation xml:lang="en">Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837848</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Butkevich A, Phillips RA, Sheinart KF, Tuhrim S. The effects of various definitions of dipping and daytime and night time on characterization of 24h profiles of blood pressure. Blood Press Monit 2000; 5: 19–22</mixed-citation><mixed-citation xml:lang="en">Butkevich A, Phillips RA, Sheinart KF, Tuhrim S. The effects of various definitions of dipping and daytime and night time on characterization of 24h profiles of blood pressure. Blood Press Monit 2000; 5: 19–22</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
